Periampullary Cancer Clinical Trial
Official title:
A Prospective, Single-center, Single-group Clinical Study for Evaluating the Clinical Safety and Effectiveness of the Automated Robotic Robot, Revo-i Surgical Robot System (Model MSR-5100), Used for General Endoscopic Surgery.
This study is based on the ergonomic features of the most common surgical procedures, which require advanced techniques and relatively difficult operations, such as pancreatobiliary surgery, prostatectomy, nephrectomy, colon and rectal resection. This study id designed to verify the clinical safety and effectiveness of 'Revo-i Surgical Robot System (Model MSR-5100), developed by Mirae Company to overcome the limitations of general laparoscopic surgery.
Status | Recruiting |
Enrollment | 33 |
Est. completion date | April 2020 |
Est. primary completion date | March 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: All of the following selection criteria must be met to be enrolled in this clinical trial. - Common Standard 1. Adults over 19 2. Voluntary consent to clinical research and willingness to comply with the protocol - Pancreaticobiliary tract area surgery 1. A person deemed to need surgery for pancreaticobiliary tract due to one or more of the following reasons: - Benign and borderline periampullary cancer - Resectable masses (biliary cancer, pancreatic cancer, duodenal cancer, AoV cancer, etc.) Congenital gallbladder cysts - Endoscopic treatment of adenocarcinoma and early stage lesions of ampulla - There is no major organ or vascular invasion - Lack of severe pancreatitis and cholangitis 2. Patients considering laparoscopic surgery who cannot perform da Vinci robot surgery due to personal expense 3. Others who have been diagnosed with high latitude pancreaticobiliary tract surgery according to the researcher's judgment - Prostatectomy 1. Persons deemed necessary for prostatectomy in the following cases: -The prostate is at low risk or medium risk, and the tumor is located at the local site without metastasis Criteria for Prostate Risk Group Prostate low risk group Prostate Cancer Stage (T1-T2a) and Gleason Grade =6 and PSA <10ng / ml Risk group in the prostate Prostate cancer stage (T2b-T2c) or Gleason grade 7 or10 ng / ml = PSA = 20 ng / ml * Reference) NCCN (National Comprehensive Cancer Network), 2015 2. Others who have been diagnosed as requiring prostate surgery according to the researcher's judgment - Nephrectomy 1. Persons deemed necessary for renal resection should: Localized renal cell carcinoma without metastasis to organs other than the kidney Stage 1A, IB, II, III * Reference) NCCN (National Comprehensive Cancer Network), 2011 2. Others who have been diagnosed with nephrectomy according to the researcher's judgment - Colon and Rectal Surgery 1. A person who needs to have a resection for colon and rectal cancer - Histopathologically confirmed by adenocarcinoma of the rectum or colon - No remote transition (M0) - Primary tumor without other peripheral organ involvement (T1-T4a) - When intestinal obstruction is not accompanied In case of elective surgery - Does not require resection of any organ other than the primary tumor 2. Others who have been diagnosed as having to need colon and rectal resection according to the researcher's judgment Exclusion Criteria: - Common Standard 1. If you have mental illness or serious systemic disease 2. Body Mass Index (BMI) = 30, high obesity 3. General anesthesia is not possible due to uncontrolled bleeding tendency or lowering of cardiopulmonary function 4. If you have a positive or reactive pregnancy 5. Patients who wish to undergo conventional laparoscopy or da Vinci robotic surgery - Pancreaticobiliary tract area surgery -If you have a history of open abdominal surgery Liver cirrhosis Patients with abnormally inoperable pancreatobiliary malformations, other pancreatic biliary diseases, or systemic diseases - Prostatectomy 1. Surgical removal of prostate tumor is difficult or life expectancy is short 2. Meets the exclusion criteria of prostatectomy below <Exclusion Criteria for Prostatectomy> - Clinical study subjects at high risk group Criteria of Prostate Risk Group Prostate High Risk Group Prostate Cancer Stage (T3a and above) or Gleason class = 8 or = 10 or PSA> 20ng / ml * Reference) NCCN (National Comprehensive Cancer Network), 2015 - Have a history of surgery on the prostate, urethra, or bladder neck - If you have a history of open surgery - Nephrectomy 1. If you have a history of epigastric open surgery or have had kidney surgery 2. History of chronic inflammation in the kidneys and the posterior cavity 2) prone to bleeding 3) When a disease such as kidney or vascular malformation is impossible to the extent that surgery is impossible - Colon and Rectal Surgery 1. If you have a history of lower abdominal and pelvic laparotomy 2. prone to bleeding 3. If you are older than 80 years old 4. In case of remote transition (M1) 5. When long-term complications other than adjacent organ invasion (T4b) or primary tumor are needed 6. Accompanied by intestinal obstruction, perforation, or emergency surgery |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Department of Surgery, Yonsei University College of Medicine | Seoul |
Lead Sponsor | Collaborator |
---|---|
Yonsei University |
Korea, Republic of,
Menon M, Shrivastava A, Tewari A, Sarle R, Hemal A, Peabody JO, Vallancien G. Laparoscopic and robot assisted radical prostatectomy: establishment of a structured program and preliminary analysis of outcomes. J Urol. 2002 Sep;168(3):945-9. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Operation success rate | Surgery is complete without significant complications up to 24 hours after surgery and without conversion to other operations (laparotomy or laparoscopy) | 24hours after operation | |
Secondary | Operative outcome | Operation time (minute) | immediate postoperation | |
Secondary | Operative outcome | Intraoperative bleeding volume (ml) | immediate postoperation | |
Secondary | Operative outcome | Length of stay (day) | 1 month after operation | |
Secondary | Operative outcome | Complication rate (%) | 1 month after operation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06009224 -
The Effect of ERAS on Pancreaticoduodenectomy (v2.0)
|
N/A | |
Recruiting |
NCT05155878 -
Prognostic Factors in Periampullary Tumors and Cysts
|
||
Recruiting |
NCT03724994 -
Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer
|
||
Recruiting |
NCT03063554 -
EUS BD vs ERCP TP for Pancreatic Cancer
|
N/A | |
Completed |
NCT03870698 -
Comparison of Functional Recovery Between Laparoscopic and Open Pancreaticoduodenectomy
|
N/A | |
Terminated |
NCT04311047 -
Preoperative Detection of Lymph Node Metastases in Pancreatic and Periampullary Carcinoma Using USPIO MRI
|
N/A | |
Not yet recruiting |
NCT06381882 -
The Role of the Human Microbiome in Patients After Pancreatic Resection.
|
||
Recruiting |
NCT03138213 -
Comparing Total Laparoscopic Versus Open Pancreaticoduodenectomy
|
N/A | |
Withdrawn |
NCT01913275 -
Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy
|
N/A | |
Completed |
NCT04401722 -
Clinical Impact of Altitude Level on Surgical Outcomes of Pancreaticoduodenectomy
|
N/A | |
Not yet recruiting |
NCT05843877 -
Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula
|
Phase 3 | |
Completed |
NCT02787512 -
Preoperative Biliary Drainage With Metal Versus Plastic Stents in Periampullary Cancer
|
N/A | |
Completed |
NCT02900950 -
Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer
|
N/A | |
Recruiting |
NCT06069297 -
Prehabilitation in Pancreatic Surgery
|
N/A | |
Completed |
NCT01789502 -
Comparison Between Fully Covered Metal Stents and Plastic Stents in Preoperative Biliary Drainage
|
N/A | |
Suspended |
NCT04714983 -
DNX-2440 for Resectable Colorectal Liver Metastasis
|
Phase 1 | |
Terminated |
NCT05289830 -
Escitalopram to Placebo in Patients With Localized Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT04289831 -
Preoperative Biliary Drainage in Patients With Operable Malignant Periampulary Tumors
|
N/A | |
Completed |
NCT00841607 -
Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy
|
N/A | |
Completed |
NCT04985071 -
Complication of Pancreatic Fistula and Bleeding After Pancreaticoduodenectomy in Treatment Periampullary Cancer
|